Apotex and Grünenthal entered into a licensing agreement that gives Apotex exclusive Canadian rights to Nebido®.[1][2][3] Nebido® is a long-acting injectable therapy containing testosterone undecanoate intended for the treatment of male hypogonadism, i.e. testosterone deficiency in adult men.[1][2][3] Under the agreement, Apotex's Searchlight Pharma division will obtain marketing authorization and distribute the drug in the Canadian market.[1][2][3] The injection is administered directly by the doctor every 10 to 14 weeks.[1][2][3] This agreement will deepen existing collaborations between the companies and promote Canadian patient access to this therapy.[1][2][3] Grünenthal will receive an upfront payment, regulatory milestone payments and a share of the sale's profits.[3] The agreement was announced on February 5, 2026 in Aachen, Germany and Toronto, Canada.[1][2][3]